1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14
1.2 MARKET SYNOPSIS 14
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16
3.2 DATA MINING 16
3.3 SECONDARY RESEARCH 16
3.4 PRIMARY RESEARCH 18
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING METHODS 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 22
3.8 VALIDATION 22
3.9 ASSUMPTIONS AND LIMITATIONS 23
3.9.1 ASSUMPTIONS AND LIMITATIONS 23
3.9.2 MARKET FACTORS 23
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 INCREASING NUMBER OF COVID-19 CASES 26
4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26
4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26
4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27
4.3 RESTRAINTS 28
4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28
4.3.2 ACCURACY OF TEST RESULTS 28
4.4 OPPORTUNITIES 28
4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28
4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28
5 MARKET FACTOR ANALYSIS
5.1 PORTERโS FIVE FORCES MODEL 29
5.1.1 THREAT OF NEW ENTRANTS 29
5.1.2 BARGAINING POWER OF SUPPLIERS 30
5.1.3 THREAT OF SUBSTITUTES 30
5.1.4 BARGAINING POWER OF BUYERS 30
5.1.5 INTENSITY OF RIVALRY 30
5.2 SUPPLY CHAIN ANALYSIS 31
5.2.1 R&D AND DESIGNING 32
5.2.2 MANUFACTURING 32
5.2.3 DISTRIBUTION 32
5.2.4 MARKETING & SALES 32
5.2.5 POST-SALES MONITORING 32
5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32
6 COVID-19 DIAGNOSTICS MARKET, BY TYPE
6.1 OVERVIEW 33
6.2 MOLECULAR TESTS 34
6.3 SEROLOGY TESTS 36
7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW 38
7.2 RT-PCR 40
7.3 ISOTHERMAL AMPLIFICATION 40
7.4 CRISPR 41
7.5 ELISA 42
7.6 HYBRIDIZATION 43
7.7 OTHERS 43
8 COVID-19 DIAGNOSTICS MARKET, BY END USER
8.1 OVERVIEW 44
8.2 HOSPITALS 45
8.3 PUBLIC HEALTH LABS 46
8.4 PRIVATE OR COMMERCIAL LABS 47
9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION
9.1 OVERVIEW 48
9.2 EUROPE 50
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1 WESTERN EUROPE 52
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.1 GERMANY 53
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.2 SPAIN 54
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.3 ITALY 55
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.4 UK 56
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.5 FRANCE 57
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.6 REST OF WESTERN EUROPE 58
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.2 EASTERN EUROPE 59
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3 AMERICAS 61
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1 NORTH AMERICA 63
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.1 US 64
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.2 CANADA 65
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.2 LATIN AMERICA 66
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4 ASIA-PACIFIC 68
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.1 INDIA 70
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.2 AUSTRALIA 71
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.3 SOUTH KOREA 72
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.4 JAPAN 73
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.5 CHINA 74
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 75
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 77
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.1 MIDDLE EAST 79
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.2 AFRICA 80
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 81
10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81
10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82
10.4 COMPETITIVE BENCHMARKING 83
10.5 COMPETITOR DASHBOARD 84
10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85
10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86
10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86
10.8.1 PRODUCT LAUNCHES 87
10.8.2 ACQUISITIONS 88
10.8.3 CONTRACTS 88
11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY 89
11.1.1 COMPANY OVERVIEW 89
11.1.2 FINANCIAL OVERVIEW 90
11.1.3 PRODUCTS/SERVICES OFFERED 90
11.1.4 KEY DEVELOPMENTS 91
11.1.5 SWOT ANALYSIS 91
11.1.6 KEY STRATEGIES 91
11.2 BIO-RAD LABORATORIES, INC. 92
11.2.1 COMPANY OVERVIEW 92
11.2.2 FINANCIAL OVERVIEW 92
11.2.3 PRODUCTS/SERVICES OFFERED 93
11.2.4 KEY DEVELOPMENTS 93
11.2.5 SWOT ANALYSIS 94
11.2.6 KEY STRATEGIES 94
11.3 DANAHER CORPORATION 95
11.3.1 COMPANY OVERVIEW 95
11.3.2 FINANCIAL OVERVIEW 96
11.3.3 PRODUCTS/SERVICES OFFERED 96
11.3.4 KEY DEVELOPMENTS 97
11.3.5 SWOT ANALYSIS 97
11.3.6 KEY STRATEGIES 97
11.4 ABBOTT 98
11.4.1 COMPANY OVERVIEW 98
11.4.2 FINANCIAL OVERVIEW 99
11.4.3 PRODUCTS/SERVICES OFFERED 99
11.4.4 KEY DEVELOPMENTS 100
11.4.5 SWOT ANALYSIS 100
11.4.6 KEY STRATEGIES 100
11.5 F. HOFFMANN-LA ROCHE LTD 101
11.5.1 COMPANY OVERVIEW 101
11.5.2 FINANCIAL OVERVIEW 102
11.5.3 PRODUCTS/SERVICES OFFERED 102
11.5.4 KEY DEVELOPMENTS 103
11.5.5 SWOT ANALYSIS 103
11.5.6 KEY STRATEGIES 103
11.6 BIOMรRIEUX SA 104
11.6.1 COMPANY OVERVIEW 104
11.6.2 FINANCIAL OVERVIEW 104
11.6.3 PRODUCTS/SERVICES OFFERED 105
11.6.4 PRODUCTS/SERVICES PIPELINE 105
11.6.5 KEY DEVELOPMENTS 105
11.6.6 SWOT ANALYSIS 106
11.6.7 KEY STRATEGIES 106
11.7 GENMARK DIAGNOSTICS, INC. 107
11.7.1 COMPANY OVERVIEW 107
11.7.2 FINANCIAL OVERVIEW 107
11.7.3 PRODUCTS/SERVICES OFFERED 108
11.7.4 KEY DEVELOPMENTS 108
11.7.5 SWOT ANALYSIS 108
11.7.6 KEY STRATEGIES 108
11.8 THERMO FISHER SCIENTIFIC INC. 109
11.8.1 COMPANY OVERVIEW 109
11.8.2 FINANCIAL OVERVIEW 109
11.8.3 PRODUCTS/SERVICES OFFERED 110
11.8.4 KEY DEVELOPMENTS 110
11.8.5 SWOT ANALYSIS 110
11.8.6 KEY STRATEGIES 111
11.9 QIAGEN 112
11.9.1 COMPANY OVERVIEW 112
11.9.2 FINANCIAL OVERVIEW 113
11.9.3 PRODUCTS/SERVICES OFFERED 113
11.9.4 KEY DEVELOPMENTS 114
11.9.5 SWOT ANALYSIS 114
11.9.6 KEY STRATEGIES 114
11.10 SIEMENS AG 115
11.10.1 COMPANY OVERVIEW 115
11.10.2 FINANCIAL OVERVIEW 115
11.10.3 PRODUCTS/SERVICES OFFERED 116
11.10.4 KEY DEVELOPMENTS 116
11.10.5 SWOT ANALYSIS 116
11.10.6 KEY STRATEGIES 117
12 APPENDIX
12.1 REFERENCES 118
12.2 RELATED REPORTS 119
13 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS AND LIMITATIONS 23
TABLE 2 NUMBER OF NEW CASES IN COUNTRIES THAT ARE MOST AFFECTED BY COVID-19 AS OF 18 MAY 2022 26
TABLE 3 DEVELOPMENTS BY PHARMACEUTICAL COMPANIES TO BOOST THE TESTING OF COVID-19 27
TABLE 4 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 34
TABLE 5 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 MOLECULAR TESTS DURING THE PUBLIC HEALTH EMERGENCY 35
TABLE 6 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR MOLECULAR TESTS, BY REGION, 2022-2030 (USD MILLION) 35
TABLE 7 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 SEROLOGICAL TESTS DURING THE PUBLIC HEALTH EMERGENCY 36
TABLE 8 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR SEROLOGY TESTS, BY REGION, 2022-2030 (USD MILLION) 37
TABLE 9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 39
TABLE 10 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR RT-PCR, BY REGION, 2022-2030 (USD MILLION) 40
TABLE 11 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ISOTHERMAL AMPLIFICATION TECHNOLOGY 41
TABLE 12 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ISOTHERMAL AMPLIFICATION, BY REGION, 2022-2030 (USD MILLION) 41
TABLE 13 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR CRISPR, BY REGION, 2022-2030 (USD MILLION) 42
TABLE 14 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ELISA 42
TABLE 15 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ELISA, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 16 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HYBRIDIZATION, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 17 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 45
TABLE 18 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 19 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PUBLIC HEALTH LABS, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 20 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PRIVATE OR COMMERCIAL LABS, BY REGION, 2022-2030 (USD MILLION) 47
TABLE 21 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 49
TABLE 22 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 50
TABLE 23 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 51
TABLE 24 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 51
TABLE 25 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 51
TABLE 26 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 52
TABLE 27 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 52
TABLE 28 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 53
TABLE 29 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 53
TABLE 30 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 53
TABLE 31 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 54
TABLE 32 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 54
TABLE 33 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 54
TABLE 34 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 55
TABLE 35 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 55
TABLE 36 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 55
TABLE 37 ITALY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 56
TABLE 38 UK: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 56
TABLE 39 UK: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 56
TABLE 40 UK: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 57
TABLE 41 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 57
TABLE 42 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 57
TABLE 43 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 58
TABLE 44 REST OF WEST